MASLD的影像学检查:临床标准与新兴方法
本综述总结了用于代谢功能障碍相关脂肪性肝病(MASLD)诊断与分期的现有及新兴影像技术,重点阐述其测量原理、诊断性能与实际局限性。常规超声仍是脂肪变性筛查最广泛使用的一线方法,而MRI衍生的质子密度脂肪分数和质子磁共振波谱被视为定量肝脂含量的无创参考标准;磁共振弹性成像在纤维化分期方面提供最高的无创准确性。新兴的分子影像和代谢成像技术有望更特异地评估纤维生成和炎症,但目前仅限于研究环境。
要点
- 常规超声是脂肪变性筛查最广泛使用的一线方法,但对轻度脂肪变性敏感性不足且高度依赖操作者和体型。
- MRI衍生的质子密度脂肪分数和质子磁共振波谱是无创定量肝脂含量的参考标准,即使低脂肪分数也具有高敏感性和特异性。
- 磁共振弹性成像在纤维化分期方面提供最高的无创准确性,而瞬时弹性成像因更广泛的可及性在常规护理中更常用。
核心结论
- 影像学在MASLD诊断与分期中居核心地位,未来有望成为活检的无创替代方法。
研究设计与样本
- 综述,总结用于MASLD诊断与分期的现有及新兴影像技术的测量原理、诊断性能和实际局限性。
主要发现
- 常规超声是脂肪变性筛查最广泛使用的一线方法,但对轻度脂肪变性缺乏敏感性且高度依赖操作者和体型。
- 定量超声扩展如受控衰减参数改善脂肪变性评估,瞬时弹性成像还可测量肝硬度作为纤维化的替代标志物。
- CT可基于密度评估脂肪变性和局灶性病变,但受辐射暴露和对低肝脂含量敏感性差的限制。
- MRI衍生的质子密度脂肪分数和质子磁共振波谱被视为定量肝脂含量的无创参考标准,即使低脂肪分数也具有高敏感性和特异性,但成本更高且可及性受限。
- 磁共振弹性成像在纤维化分期方面提供最高的无创准确性并通过探测大体积肝脏减少采样误差,而瞬时弹性成像因更广泛可及性在常规护理中更常用。
临床怎么用
- 常规超声可作为脂肪变性筛查的首选一线方法,但需注意其对轻度脂肪变性的敏感性和操作者依赖性。
- MRI衍生的质子密度脂肪分数和质子磁共振波谱可用于无创定量肝脂含量,尤其适用于需要精确评估的场景。
- 磁共振弹性成像可用于纤维化分期的高准确性无创评估,瞬时弹性成像则因更广泛可及性适合常规护理。
局限性
- 常规超声对轻度脂肪变性缺乏敏感性且高度依赖操作者和体型。
- CT受辐射暴露和对低肝脂含量敏感性差的限制。
- MRI衍生技术成本更高且可及性受限。
- 基于MRI的扩散加权成像和T1映射技术的特异性和标准化仍在评估中。
- 新兴分子影像和代谢成像技术目前仅限于研究环境。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Non-invasive imaging is central to the diagnosis and staging of metabolic dysfunction-associated steatotic liver disease (MASLD). Various non-invasive means are used to reliably diagnose steatosis, whereas liver biopsy remains the gold standard for MASLD staging, as it enables assessment of the severity of fibrosis and inflammation. Importantly, imaging modalities have the potential to serve as non-invasive alternatives to biopsy in the future. This review summarises established and emerging imaging techniques for the diagnosis and staging of MASLD, focusing on their measurement principles, diagnostic performance and practical limitations. Conventional ultrasound remains the most widely used first-line modality for steatosis screening owing to its low cost and broad availability, but it lacks sensitivity for mild steatosis and is strongly operator and body habitus dependent. Quantitative ultrasound extensions such as the controlled attenuation parameter improve steatosis assessment, while transient elastography additionally measures liver stiffness, which is a surrogate marker for fibrosis. Computed tomography permits density-based assessment of steatosis and focal lesions but is limited by radiation exposure and poor sensitivity for low hepatic lipid (HL) content. MRI-derived proton density fat fraction and proton magnetic resonance spectroscopy are considered non-invasive reference standards for quantifying HL content, with high sensitivity and specificity even at low fat fractions, albeit at a higher cost and with more restricted availability. For fibrosis staging based on liver stiffness, magnetic resonance elastography currently offers the highest non-invasive accuracy across fibrosis stages and reduces sampling error by probing large liver volumes, whereas transient elastography is more widely implemented in routine care owing to its broader availability. Additional MRI-based approaches, including diffusion-weighted imaging and T1-based mapping techniques, provide complementary information on tissue microstructure, reflecting inflammatory and fibrotic processes, although their specificity and standardisation are still under evaluation. Nuclear imaging with positron emission tomography and single-photon emission computed tomography enables functional and molecular characterisation. Novel tracers targeting fibroblast activation protein, macrophage subsets or activated hepatic stellate cells, together with targeted MRI contrast agents and nanoparticle-based probes, hold promise for more specific imaging of fibrogenesis and inflammation. Beyond structural changes, multinuclear magnetic resonance spectroscopy and specialised positron emission tomography tracers allow in vivo assessment of hepatic energy metabolism, mitochondrial function, glycogen dynamics and substrate fluxes, which is particularly relevant for mechanistic studies, increasing our understanding of MASLD pathology, but are currently confined to research settings. Future developments will likely emphasise multiparametric and multimodal strategies integrating quantitative imaging biomarkers with clinical and biochemical data to refine risk stratification, enable sensitive treatment monitoring and support precision medicine approaches in MASLD.
引用
- Jonuscheit M, Schrauwen-Hinderling VB. Imaging of MASLD: clinical standards and novel methods. Diabetologia. 2026. PMID: 42461275. doi:10.1007/s00125-026-06799-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。